Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Merck & Co., Inc. (NYSE:MRK) is a leading pharmaceutical company, best known for its strong presence in oncology, ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has become ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

To read all of these articles and more, visit centerforbiosimilars.com.